GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Capex-to-Revenue

Orphazyme AS (CHIX:ORPHAC) Capex-to-Revenue : 0.00 (As of Jun. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Orphazyme AS's Capital Expenditure for the three months ended in Jun. 2022 was kr0.00 Mil. Its Revenue for the three months ended in Jun. 2022 was kr0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Orphazyme AS Capex-to-Revenue Historical Data

The historical data trend for Orphazyme AS's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Capex-to-Revenue Chart

Orphazyme AS Annual Data
Trend Jun14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Capex-to-Revenue
Get a 7-Day Free Trial - - - - 0.03

Orphazyme AS Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.01 -

Competitive Comparison of Orphazyme AS's Capex-to-Revenue

For the Biotechnology subindustry, Orphazyme AS's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orphazyme AS's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orphazyme AS's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Orphazyme AS's Capex-to-Revenue falls into.



Orphazyme AS Capex-to-Revenue Calculation

Orphazyme AS's Capex-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.994) / 36.193
=0.03

Orphazyme AS's Capex-to-Revenue for the quarter that ended in Jun. 2022 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orphazyme AS  (CHIX:ORPHAc) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Orphazyme AS Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Orphazyme AS (CHIX:ORPHAC) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200
Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines